Product & Industry News
Drug Discovery World
Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate

17 June 2020

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic. 

Cobra hit the ground running with AstraZeneca and other manufacturing organisations to provide large scale manufacturing capacity of AZD1222 vaccine. Cobra, along with other consortium members, will be manufacturing the vaccine with first deliveries to begin in the UK in September 2020. 

The agreement is a further development of Cobra’s announcement in March 2020, that the company is working as part of a consortium with the Jenner Institute, University of Oxford, and others, to rapidly develop, scale-up and produce the recombinant adenovirus vector ChAdOx1 nCoV-19. 

Peter Coleman, chief executive at Cobra Biologics, said: “I am extremely proud of the contribution made by the Cobra team alongside our consortium partners and despite the current restrictive requirements in place, the progress being made with demanding timelines is outstanding.  Cobra’s considerable expertise in GMP viral vector scale up and manufacture will be critical to a successful manufacturing campaign. The agreement with AstraZeneca comes at an opportune time for us as we bring three additional viral vector suites online as part of our ongoing advanced therapies expansion programme.”

More on this subject...
Drug Discovery World

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate READ MORE

Drug Discovery World

Insect-based technology for human vaccines READ MORE

Drug Discovery World

Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe READ MORE

Drug Discovery World

Avacta collaboration offers update on Affimer therapy for COVID-19 READ MORE

Drug Discovery World

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago READ MORE

Drug Discovery World

Taconic Biosciences to distribute critical COVID-19 mouse model READ MORE

Drug Discovery World

Symbiosis to manufacture COVID-19 vaccine for clinical trials READ MORE

Drug Discovery World

Avacta positive on evaluation of COVID-19 test strips READ MORE

Drug Discovery World

PrecisionLife identifies 68 genes associated with risk of severe COVID-19 READ MORE

Drug Discovery World

Imaging system produces human cellular morphological data for COVID-19 research READ MORE